Organisational matters

Scientific coordinators

Prof. Dr. Andreas Fellgiebel, Department of Psychiatry and Psychotherapy, University Medical Center of Mainz; Department of Gerontopsychiatry, Rheinhessen-Fachklinik Alzey

Prof. Dr. Stefan Teipel, Department of Psychosomatic Medicine, University Rostock; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)

Prof. Dr. Osama Sabri and Prof. Dr. Henryk Barthel, Department of Nuclear Medicine, University of Leipzig

Prof. Dr. Alexander Drzezga, Department of Nuclear Medicine, University Hospital of Cologne

Registration

Please register until 31.08.2016 (limited number of participants) via

E-Mail: irene.lelieveld@unimedizin-mainz.de
Fax: +49 (0) 6131 176690

under specification of:

Title, Last name, First name
Hospital Affiliation / Name of Organisation
Mailing Address (Street, Zip Code, Country)
E-Mail Address

Kloster Eberbach
Kloster-Eberbach-Straße1
65341 Eltville am Rhein

Symposium Kloster Eberbach, Germany, 16.-17.09.2016

Dementia MRI-PET Imaging platform (DeMPI)
Dear colleagues,

It is our great pleasure to invite you to the second Symposium of the Dementia MRI-PET Imaging platform (DeMPI). The Symposium aims at presenting and discussing the contribution of PET, MRI, and multimodal imaging to the understanding and diagnosis of Alzheimer’s disease (AD). We are pleased to bring together internationally renowned experts who will outline the latest advances and future directions in the field.

DeMPI is a multimodal imaging platform in Germany focusing on the early identification of healthy elderly and MCI subjects who are at risk of developing clinical AD symptoms within a personally relevant time frame. Moreover, DeMPI aims at investigating markers of cognitive reserve, resilience, and vulnerability to cerebral amyloid burden.

We look forward to welcoming you in Kloster Eberbach, a beautiful environment for a stimulating scientific exchange and lively discussions.

Best wishes

Andreas Fellgiebel
Osama Sabri
Henryk Barthel

Program
Friday, 16. September 2016
14.00 Welcome and Introduction (Andreas Fellgiebel, Stefan Teipel)
14.15-15.45 Biomarkers in AD: towards primary care (Chair: Stefan Teipel)
   - Publications that perish – or is there a better strategy for clinical research that makes a difference? (Elena Becker Baroso)
   - Use and usefulness of multimodal neuroimaging in Alzheimer’s disease: today and tomorrow (Chris Fox)
   - Validity of diagnostic and prognostic biomarkers in Alzheimer’s disease (Stephanie Vos)
16.15-18.15 Contribution of PET Imaging to Alzheimer’s disease: understanding and early diagnosis (Chairs: Osama Sabri, Alex Drzezga)
   - Increasing the sensitivity of amyloid PET for the detection of early stage amyloidosis (Michel Grothe)
   - Impact of amyloid PET on patient outcome – Introduction to the IDEAS study (Bruce Hillner)
   - PET imaging of cholinergic system neurodegeneration: a link between cognitive deficits in Parkinson’s disease and Alzheimer’s disease? (Nicolaas Bohnen)
   - Neuropathology versus neuronal dysfunction: Tau- and FDG-PET in Alzheimer’s disease (Gérard Bischof)

Program
Saturday, 17. September 2016
9.00-10.00 Multimodal imaging in Alzheimer’s disease (Chair: Alexander Drzezga)
   - Imaging neuroinflammation to complement the multimodality toolbox (Paul Edison)
   - In-vivo insights into the spatial relation between Tau and Aβ Deposits based on multi-tracer PET and functional MRI connectivity mapping (Jorge Sepulcre)
10.15-11.15 Imaging cognitive reserve and resilience (Chair: Andreas Fellgiebel)
   - White matter networks microstructure in normal aging and preclinical Alzheimer’s disease (Dominik Wolf)
   - Lifetime cognitive activity, ApoE status, and cerebral amyloid burden (Miranka Wirth)
11.15-12.15 New imaging techniques (Chair: Osama Sabri)
   - PET/MRI: Clinical use and utility (Henryk Barthel)
   - New PET targets and tracers (John Seibyl)
12.15-12.30 Closing remarks and outlook (Osama Sabri)